Bristol-Myers Squibb (NYSE:BMY) Trading 1% Higher

Bristol-Myers Squibb (NYSE:BMY) traded up 1% during trading on Friday . The stock traded as high as $41.87 and last traded at $41.43. 3,974,292 shares were traded during mid-day trading, a decline of 74% from the average session volume of 15,410,671 shares. The stock had previously closed at $41.04.

Analyst Ratings Changes

Several analysts recently commented on the stock. Societe Generale cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. Barclays reduced their price objective on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a research note on Friday, April 26th. StockNews.com cut shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday, June 17th. BMO Capital Markets reduced their price objective on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research note on Friday, April 26th. Finally, Wells Fargo & Company raised their target price on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a report on Thursday, April 18th. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $60.00.

Bristol-Myers Squibb Trading Up 2.2 %

The stock has a market capitalization of $85.00 billion, a price-to-earnings ratio of -13.53, a PEG ratio of 13.89 and a beta of 0.43. The company has a debt-to-equity ratio of 2.99, a current ratio of 1.11 and a quick ratio of 0.99. The business’s 50-day simple moving average is $43.60 and its two-hundred day simple moving average is $48.43.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($4.53) by $0.13. The firm had revenue of $11.87 billion for the quarter, compared to analysts’ expectations of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. Bristol-Myers Squibb’s revenue was up 4.7% compared to the same quarter last year. During the same period in the previous year, the company posted $2.05 earnings per share. On average, research analysts anticipate that Bristol-Myers Squibb will post 0.59 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Friday, July 5th will be given a dividend of $0.60 per share. The ex-dividend date of this dividend is Friday, July 5th. This represents a $2.40 dividend on an annualized basis and a yield of 5.72%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -77.42%.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. ESL Trust Services LLC acquired a new position in shares of Bristol-Myers Squibb during the first quarter worth $27,000. Northwest Financial Advisors acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth $27,000. Accordant Advisory Group Inc acquired a new position in shares of Bristol-Myers Squibb during the first quarter worth $31,000. Pacific Capital Wealth Advisors Inc. acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth $34,000. Finally, VisionPoint Advisory Group LLC lifted its position in shares of Bristol-Myers Squibb by 300.5% during the third quarter. VisionPoint Advisory Group LLC now owns 737 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 553 shares in the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.